

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Pancreatology 22 (2022) 539-546



Contents lists available at ScienceDirect

Pancreatology



journal homepage: www.elsevier.com/locate/pan

Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis



Feng Yang ^{a, *}, Yecheng Xu ^a, Yinlei Dong ^a, Yuting Huang ^b, Yunting Fu ^c, Tian Li ^d, Chenyu Sun ^e, Sanjay Pandanaboyana ^f, John A. Windsor ^g, Deliang Fu ^a

^a Department of Pancreatic Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China

^b Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD, USA

^c Health Sciences and Human Services Library, University of Maryland, 601 W Lombard St, Baltimore, MD, 21201, USA

^d Department of Medicine, SUNY Downstate Health and Science University, Brooklyn, NY, 11203, USA

^e Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, IL, USA

^f HPB and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK

^g Surgical and Translational Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, 1142, New Zealand

ARTICLE INFO

Article history: Received 1 September 2021 Received in revised form 14 March 2022 Accepted 16 March 2022 Available online 25 March 2022

Keywords: Amylase Lipase COVID-19 Prevalence Prognosis

ABSTRACT

Introduction: The prevalence of increased pancreatic enzymes (elevated serum amylase and/or lipase) and its relationship to clinical outcomes in patients with coronavirus disease 2019 (COVID-19) infection is not known.

Methods: A systematic review and meta-analysis of relevant studies reporting prevalence and impact of increased pancreatic enzymes (defined as an elevation in amylase and/or lipase levels above the upper limit of normal [ULN] value) in COVID-19 was undertaken.

Results: A total of 36,496 patients from 21 studies were included for this meta-analysis. The overall prevalence and mortality for increased pancreatic enzymes (>ULN) in COVID-19 were 25.4% (95% CI, 15.8%–36.2%) and 34.6% (95% CI, 25.5%–44.4%), respectively. The overall prevalence and mortality for increased pancreatic enzymes (>3 × ULN) were 6.1% (95% CI, 3.6%–9.2%) and 39.2% (95% CI, 18.7%–61.6%), respectively. Patients with increased pancreatic enzymes, including elevated serum lipase or amylase of either type, had worse clinical outcomes, including need for ICU admission, mechanical ventilation and mortality.

Discussion: Increased pancreatic enzymes is frequent and may exacerbate the consequences of COVID-19 infection.

© 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.

1. Introduction

Increased pancreatic enzymes (elevated serum amylase and/or lipase) is not necessarily diagnostic for acute pancreatitis and can occur during acute and critical illness [1], including coronavirus disease 19 (COVID-19) infection [2–4]. Subclinical direct pancreatic damage due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the exocrine pancreas has been demonstrated in previous studies [5,6]. The elevation of pancreatic enzymes has been initially reported in approximately 17% of

https://doi.org/10.1016/j.pan.2022.03.014

patients with COVID-19, but none of the patients met the revised Atlanta criteria for a diagnosis of acute pancreatitis [2]. It can be due to both increased uptake into portal vein and mesenteric lymphatics with gut injury and decreased excretion due to renal impairment [7]. Although acute pancreatitis has been reported to be associated with worse outcomes in COVID-19 [8,9], it is not known whether this is true for increased pancreatic enzymes [3,10–12]. Understanding the disease course of concomitant COVID-19 and increased pancreatic enzymes may identify patients at risk of poor outcomes and indicate early intervention. The aim of this systematic review was to determine the pooled prevalence and prognostic significance of increased pancreatic enzymes in adult patients with COVID-19.

^{*} Corresponding author.Department of Pancreatic Surgery, Pancreatic Disease Institute, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China.

E-mail addresses: yffudan98@126.com (F. Yang), surgeonfu@163.com (D. Fu).

^{1424-3903/© 2022} IAP and EPC. Published by Elsevier B.V. All rights reserved.

2. Methods

The PubMed, Embase, Scopus databases, and Cochrane library were systematically searched using the PRISMA framework for relevant reports on COVID-19 and hyperenzymemia. One of the reviewers (YTF), who is proficient in database search, designed the search strategies (Supplementary Material). The search terms used "2019-nCoV" or "SARS-CoV-2" or "COVID-19" AND "amylase" or "lipase" or "hyperamylasemia" or "hyperlipasemia" or "pancreas" or "pancreatic injury" or "pancreatitis". The records were imported into Covidence for screening. Observational studies published in English or Chinese from inception to January 20, 2022, and reported outcomes in adult patients with COVID-19 were eligible for inclusion. Duplicate reports, case reports, reviews, commentaries, editorials, small case series (<5 cases), and studies of other coronavirus-related diseases such as Middle East Respiratory Syndrome (MERS) were excluded. Two reviewers (YTH and TL) independently reviewed the records of possible relevance and assessed their eligibility. Discrepancies were resolved by a senior reviewer (FY). The references of relevant studies were manually screened for additional records. Quality assessment of included studies was performed using the Newcastle-Ottawa Scale independently by two reviewers (YCX and TL), with discrepancies resolved by another reviewer (FY).

Two reviewers (YLD and YCX) independently collected data from the included studies. Discrepancies were resolved by consensus or by a third reviewer (FY). The following variables were collected when available: authors, study location and institution, study design, study period, sample size, demographic data, comorbidities, gastrointestinal symptoms on admission, clinical outcomes including intensive care unit (ICU) admission, mechanical ventilation, and mortality. Increased pancreatic enzymes, which varied among studies due to different normal ranges, was defined as an elevation in amylase and/or lipase levels above the upper limit of normal (ULN) value. Levels higher than $3 \times$ ULN were also collected for further analysis. The primary outcome was prevalence of increased pancreatic enzymes in COVID-19. Effect of increased pancreatic enzymes on the outcomes was also assessed. A randomeffects model was used to pool the effect sizes by providing more conservative results of odds ratio (OR) and 95% confidence intervals (CI). In studies that reported both estimates of hyperamylasemia and hyperlipasemia, we combined them into a single value whenever possible, or selected the one with a higher prevalence. Statistical heterogeneity was estimated using the Cochran Q test and I² statistic. We used R (version 4.1.0) for pooling single-armed rates with Freeman-Tukey double arcsine transformation, and Review Manager (version 5.4) for other analyses. A two-tailed p-value < 0.05 was considered statistically significant.

3. Results

The initial search yielded 3,088 studies, among which 21 were included [2-4,10-27] (Fig. 1). Except for one study, all included studies had a cohort study design, and most were conducted in Europe (n = 11) or the United States (n = 5). All of the studies were retrospective in nature except two, and eight were multi-center studies (Table 1). The median score of the Newcastle-Ottawa scale was 6.

The estimated pooled prevalence of increased pancreatic enzymes (>ULN) in COVID-19 was 25.4% (95% CI, 15.8%–36.2%), whereas that of increased pancreatic enzymes (>3 × ULN) was 6.1% (95% CI, 3.6%–9.2%) (Fig. 2A and B). Only a small fraction of patients were diagnosed with acute pancreatitis (n = 594/35,906, 1.7%). The pooled prevalence of hyperlipasemia (>ULN) was 21.5% (95% CI,



Fig. 1. Study selection.

10.9%–34.3%), whereas that of hyperlipasemia (>3 × ULN) was 5.6% (95% CI, 2.8%–9.3%) (Fig. 3A and B). The pooled prevalence of hyperamylasemia (>ULN) was 21.9% (95% CI, 13.0%–32.3%), whereas that of hyperamylasemia (>3 × ULN) was 4.0% (95% CI, 0.9%–8.7%) (Supplementary Figs. 1A and 1B).

Subgroup analyses among hospitalized non-ICU patients revealed that the pooled prevalence of increased pancreatic enzymes (>ULN and >3 × ULN) was 19.4% (95% CI, 10.9%–29.5%) and 4.7% (95% CI, 2.4%–7.5%), respectively (Supplementary Figs. 2A and 2B). The pooled prevalence of hyperlipasemia (>ULN and >3 × ULN) was 17.0% (95% CI, 7.3%–29.7%) and 4.7% (95% CI, 2.1%–8.2%), respectively (Supplementary Figs. 3A and 3B). The pooled prevalence of hyperamylasemia (>ULN and >3 × ULN) was 16.7% (95% CI, 12.1%–21.9%) and 2.0% (95% CI, 0.5%–4.1%), respectively (Supplementary Figs. 4A and 4B). Among ICU patients, the pooled prevalence of increased pancreatic enzymes (>ULN and >3 × ULN) was 63.9% (95% CI, 57.0%–70.6%) and 24.5% (95% CI, 16.6%–33.3%), respectively. The pooled prevalence of hyperlipasemia (>ULN) was 58.1% (95% CI, 47.8%–68.0%).

The pooled mortality of increased pancreatic enzymes (>ULN) in COVID-19 was 34.6% (95% Cl, 25.5%–44.4%), and that of increased pancreatic enzymes (>3 × ULN) was 39.2% (95% Cl, 18.7%–61.6%) (Fig. 2C and D). The pooled mortality of hyperlipasemia (>ULN) was 31.7% (95% Cl, 23.6%–40.2%), and that of hyperlipasemia (>3 × ULN) was 30.3% (95% Cl, 13.9%–49.0%) (Fig. 3C and D). The pooled mortality of hyperamylasemia (>ULN) was 37.6% (95% Cl, 19.5%–57.5%), and that of hyperamylasemia (>3 × ULN) was 59.8% (95% Cl, 19.4%–94.7%) (Supplementary Figs. 1C and 1D).

Subgroup analyses among hospitalized non-ICU patients revealed that the pooled mortalities of increased pancreatic enzymes (>ULN and >3 × ULN) were 31.1% (95% CI, 21.5%–41.4%) and 38.8% (95% CI, 16.4%–63.5%), respectively (Supplementary Figs. 2C and 2D). The pooled mortalities of hyperlipasemia (>ULN and >3 × ULN) were 26.4% (95% CI, 21.0%–32.1%) and 30.3% (95% CI, 13.9%–49.0%), respectively (Supplementary Figs. 3C and 3D). The pooled mortalities of hyperamylasemia (>ULN and >3 × ULN) were 38.0% (95% CI, 14.6%–64.4%) and 71.0% (95% CI, 24.0%–100%), respectively (Supplementary Figs. 4C and 4D). Among ICU patients, the pooled mortality of increased pancreatic enzymes (>ULN) was 56.2% (95% CI, 15.5%–92.5%).

Compared with normal patients, those having amylase and/or lipase > ULN were more likely to have hypertension (OR, 1.27; 95% CI, 1.05–1.53; p = 0.01) and diabetes (OR, 1.48; 95%CI, 1.10–2.00; p = 0.009) (Supplementary Table 1). They had increased rates of

Table 1

Baseline characteristics of included studies wit	h hyperenzymemia in corona	virus disease 2019.
--	----------------------------	---------------------

First author	Country	Study design	Centers	Study period	Patients with COVID-19	No. of severe COVID- $19^{\$}$	Patients with AP [†]	ULN of amylase (U/L)	ULN of lipase (U/L)	Quality assessment [*]
Wang [2]	China	Retrospective	Single	2020.1.20 -2020.2.28	52	4 MV	NA	90	70	4
McNabb- Baltar [3]	USA	Retrospective	Multi	2020.1.23 -2020.4.2	71	17 ICU, 17 MV, 18 death	0	NA	60	7
Troncone [4]	Italy	Retrospective	Single	2020.3.6 -2020.5.6	254	48 ICU, 65 death	2	125 for <70 yrs, 160 for >70 yrs	78	5
Ahmed [10]	USA	Retrospective	Multi	2020.3.1 -2020.5.1	992	81 ICU ^{&} , 65 MV ^{&} , 264 death	2	NA	60 in BILH, 78 in NYULH	3
Bansal [11]	Indian	Retrospective	Single	NA	42	18 death	NA	100	81	6
Barlass [12]	USA	Retrospective	Single	2020.3.12 -2020.4.3	83	35 ICU [#] , 27 MV [#]	NA	NA	52	6
Bulthuis [13]	Netherlands	Prospective	Multi	2020.3.4 -2020.5.26	432	160 ICU, 86 death	8	NA	NA	7
Aghemo [14]	Italy	Retrospective	Single	2020.2.22 -2020.3.30	292	27 ICU, 56 death	NA	100	68	3
Akkus [15]	Turkey	Retrospective	Single	2020.3.20 -2020.6.9	127	18 ICU, 15 MV, 6 death	2	NA	60	5
Bruno [16]	Italy	Retrospective	Single	2020.2.25 -2020.5.10	70	NA	0	100	393	3
Liu [17]	China	Retrospective	Multi	2020.1.1 -2020.2.15	121	6 ICU, 7 MV, 5 death	NA	135	78	6
Pezzilli [18]	Italy	Retrospective	Single	2020.4.1 -2020.4.30	110	20 MV, 9 death	0	53	300	4
Ramsey [19]	USA	Retrospective	Multi	NA	400	211 ICU, 173 MV, 85 death	6	NA	NA	8
Rasch [20]	Germany	Prospective	Single	2020.3-2020.4	38 ^{\$}	38 ICU, 38 MV, 12 death	2	NA	60	6
Stephens	UK	Retrospective	Multi	2020.3.14 -2020.5.22	234 ^{\$}	234 ICU, 87 death	4	100	NA	5
Benias [22]	USA	Retrospective	Multi	2020.3.1 -2020.6.1	11883	391 MV ¹ , 313 death ¹	89	NA	NA	7
Singh [23]	International	Retrospective	Multi	2020.1.1 -2020.12.31	17255	127 MV ² , 263 death ²	467	NA	80	6
Ding [24]	China	Retrospective	Single	2020.1.1 -2020.3.30	55 ^{\$}	55 ICU, 31 MV, 37 death	3	135	78	5
Bacaksız [25]	Turkey	Retrospective	Single	2020.3 -2020.12	1378	469 death	6	105	65	6
Li [26]	China	Retrospective	Single	2020.1.18 -2020.3.18	1515	156 ICU, 258 MV, 118 death	0	115	NA	8
Caruso [27]	Italy	Retrospective	Single	2020.2 -2020.11	1092	86 ICU, 185 death	3	NA	55	5

AP, acute pancreatitis; BILH, Beth Israel Lahey Health; ICU, intensive care unit; MV, mechanical ventilation; NA, not available; NYULH, New York University Langone Health; ULN, upper limit of normal.

The study population was ICU patients and all other studies were hospitalized patients.

[§] Severe COVID-19 included admission to the ICU, need for MV, or death.

Diagnosis of acute pancreatitis was in accordance with the revised Atlanta criteria.

According to the Newcastle-Ottawa Scale.

& Among 157 patients with COVID-19.

Among 82 patients with COVID-19.

Among 1560 patients with COVID-19. ² Among 2812 patients with COVID-19.

ICU admission (OR, 3.90; 95%CI, 2.59–5.87; p < 0.00001), need for mechanical ventilation (OR, 2.90; 95%CI, 2.03-4.14; p < 0.00001), and mortality (OR, 2.36; 95%CI, 1.58–3.51; p < 0.0001). Comparing amylase and/or lipase >3 vs < 3 \times ULN, the ORs (95%CI) of ICU admission, need for mechanical ventilation and mortality were 7.04 (3.86–12.86), 2.76 (1.26–6.03), and 2.35 (1.32–4.16), respectively (Supplementary Fig. 5).

Compared with normal patients, those having lipase > ULN were more likely to have hypertension (OR, 1.26; 95%CI, 1.01–1.58; p = 0.04) (Supplementary Table 1). They had increased rates of ICU admission (OR, 3.30; 95%CI, 2.30-4.72; p < 0.00001), need for mechanical ventilation (OR, 2.24; 95%CI, 1.81–2.77; p < 0.00001), and mortality (OR, 1.66; 95%CI, 1.42-1.94; p < 0.00001). Comparing lipase >3 vs < 3 \times ULN, the ORs (95%CI) of ICU admission, need for mechanical ventilation and mortality were 6.10 (3.86-9.65), 2.76 (1.26-6.03), and 1.70 (1.22-2.38), respectively (Fig. 4).

4. Discussion

The exact pathophysiologic mechanism regarding pancreatic involvement of COVID-19 remains fully unknown. Based on the results of this meta-analysis, increased pancreatic enzymes was found in about 20% of hospitalized patients with COVID-19, which was notably higher than earlier studies [2,3,14–17,28]. The obvious reason for increased pancreatic enzymes in COVID-19 patients is concomitant acute pancreatitis, which is thought to be related to rich expression of angiotensin converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in pancreatic ductal cells [29,30]. Autopsy findings showed that pancreatitis and fat necrosis occurred in 20-40% cases of lethal patients with COVID-19 [31,32]. However, consistent with the result of a previous metaanalysis [9], acute pancreatitis occurred in very few patients (1.7%) in this study. The high prevalence may also be due to COVID-



Fig. 2. Pooled prevalence of increased pancreatic enzymes (A > ULN, B > 3 × ULN) and mortality (C > ULN, D > 3 × ULN) in patients with COVID-19. ULN, upper limit of normal.



Fig. 3. Pooled prevalence of hyperlipasemia (A > ULN, B > 3 × ULN) and mortality (C > ULN, D > 3 × ULN) in patients with COVID-19.

Α	Increased	lipase	Normal lin	oase		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random. 95% CI		M-H, Random, 95% Cl	
Ahmed, et al	37	56	44	101	17.3%	2.52 [1.28, 4.97]			
Akkus, et al	6	20	12	107	8.3%	3.39 [1.10, 10.50]			
Caruso, et al	55	344	31	748	26.0%	4.40 [2.78, 6.98]			
McNabb-Baltar, et al	4	9	13	62	5.4%	3.02 [0.71, 12.86]			
Ramsey, et al	66	100	145	300	25.5%	2.08 [1.29, 3.33]			
Troncone, et al	26	62	22	192	17.5%	5.58 [2.85, 10.93]			
Total (95% CI)		591		1510	100.0%	3.30 [2.30, 4.72]		-	
I otal events	194	0.00 46-	267	D. 17 - O	201		Ē		_
Heterogeneity: I au* =	0.07; Chi*=	8.20, at =	5 (P = 0.15	0; 1*= 39	1%		0.01	0.1 1 10 10	o'
restion overall ellect.	Z = 0.02 (F %	0.00001	,					Normal lipase Increased lipase	
D									
В	Increased	lipase	Normal lip	pase		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Ahmed, et al	31	56	34	101	10.1%	2.44 [1.25, 4.77]			
Akkus, et al	5	20	10	107	3.2%	3.23 [0.97, 10.77]			
Benias, et al	111	316	257	1155	59.8%	1.89 [1.45, 2.48]		—	
Ding, et al	24	32	12	23	3.2%	6.86 [2.07, 22.66]			
Monapp-Baitar, et al	4	400	13	200	2.2%	3.02 [0.71, 12.80]			
Manna et el	1	100	3	300	20.0%	2.03 [1.03, 4.10]			
wang, et al		5	5	47	0.7 70	0.07 [0.01, 40.00]			
Total (95% CI)		538		1795	100.0%	2.24 [1.81, 2.77]		•	
Total events	237		436						
Heterogeneity: Tau ² =	0.00; Chi ² =	6.06, df =	6 (P = 0.42); I ² = 19	%		H-01		1
Test for overall effect:	Z = 7.37 (P <	0.00001))				0.01	Normal linase Increased linase	U
								Normanipase increased ipase	
C	Increased	linese	Manuallin			Odda Datia		Orlda Datia	
Study or Subgroup	Evente	Total	Normal II	Total	Moight	M H Bandom 05% Cl		Odds Ratio	
Abroad at al	126	10120	120	662	20.00%	1 50 (1 10 2 00)			_
Anmeu, et al	130	429	120	107	29.0%	2 96 10 40 46 70			
Rancal et al	2	20	9	22	0.0%	2.00 [0.49, 10.79]			
Benias et al	85	316	216	1155	28.5%	1 60 [1 20 2 14]		-	
Caruso, et al	73	344	112	748	22.3%	1.53 [1.10, 2.12]			
Ding, et al	25	32	12	23	1.7%	3.27 [1.01, 10.56]			
McNabb-Baltar, et al	3	9	15	62	1.1%	1.57 [0.35, 7.04]			
Ramsey, et al	28	100	57	300	8.7%	1.66 [0.98, 2.80]			
Troncone, et al	25	62	40	192	6.3%	2.57 [1.39, 4.75]			
Total (95% CI)		1319		31/2	100.0%	16611/2 19/1			
Total success	204		600	0	1001010	1.00[1.42, 1.54]			
Total events	381	4 17 df-	592 9 /P = 0.94	N-12-00	v	1.00 [1.42, 1.34]	<u> </u>		-
Total events Heterogeneity: Tau ² = Test for overall effect:	381 0.00; Chi² = 7 = 6.45 (P ≼	4.17, df =	592 8 (P = 0.84); ² = 09	%	1.00 [1.42, 1.34]	L 0.01	0.1 1 10 10	- U
Total events Heterogeneity: Tau ² = Test for overall effect: .	381 0.00; Chi² = Z = 6.45 (P <	4.17, df= 0.00001)	592 8 (P = 0.84)); ² = 09	%	1.00 [1.42, 1.34]	L 0.01	0.1 1 10 100 Normal lipase Increased lipase	To
Total events Heterogeneity: Tau ² = Test for overall effect: J	381 0.00; Chi ^z = Z = 6.45 (P <	4.17, df= 0.00001)	592 8 (P = 0.84)); I ² = 09	%	1.00 [1.42, 1.34]	L	0.1 1 10 10 Normal lipase	Τo
Total events Heterogeneity: Tau ² = Test for overall effect: J	381 0.00; Chi ² = Z = 6.45 (P < Lipase >3)	4.17, df= 0.00001) • ULN	592 8 (P = 0.84) Lipase <3 >	(ULN	%	Odds Ratio	L 0.01	0,1 1 10 10 Normal lipase Increased lipase	Τo
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup	381 0.00; Chi ^z = Z = 6.45 (P < Lipase >3 > Events	4.17, df= : 0.00001) * ULN <u>Total</u>	592 8 (P = 0.84) Lipase <3 × Events	(ULN); ² = 09	Weight	Odds Ratio M-H, Random, 95% CI	0.01	0.1 1 10 100 Normal lipase Increased lipase Odds Ratio <u>M-H, Random, 95% Cl</u>	To
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al	381 0.00; Chi ^z = Z = 6.45 (P < Lipase >3 ; Events 20	4.17, df= : 0.00001) * ULN 1 <u>Total</u> 26	592 8 (P = 0.84) Lipase <3 > Events 61	(ULN) 131	Weight 22.1%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14]	L 0.01	0.1 1 10 10 Normal lipase Increased lipase Odds Ratio <u>M-H. Random, 95% Cl</u>	To .
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al	381 0.00; Chi ^z = Z = 6.45 (P < Lipase >3 × Events 20 13 20	4.17, df= :0.00001) * ULN 1 <u>Total</u> 26 14	592 8 (P = 0.84) Lipase <3 > <u>Events</u> 61 22	(ULN) (ULN) (131) (132)	Weight 22.1% 4.8%	Odds Ratio M-H, Random, 95% CI 3.83 (1.44, 10.14) 27.18 (3.34, 221.18)	0.01	0.1 1 10 100 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al	381 0.00; Chi ² = Z = 6.45 (P < Lipase >3 ; Events 20 13 20 5	4.17, df = :0.00001) * ULN 1 <u>Total</u> 26 14 65 0	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 42	• ULN • ULN 131 68 1027	Weight 22.1% 4.8% 61.7%	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.927 (6.42) 23.27	0.01	0,1 1 10 100 Normal lipase Increased lipase Odds Ratio M-H, Random, 95% Cl	
Total events Heterogeneity: Tau ^a = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al	381 0.00; Chi ² = Z = 6.45 (P < Lipase >3 - Events 20 13 20 5	4.17, df= : 0.00001) * ULN 1 <u>Total</u> 26 14 65 9	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43	 ULN 12 = 09 ULN 131 68 1027 245 	Weight 22.1% 4.8% 61.7% 11.4%	Odds Ratio <u>M-H, Randorn, 95% CI</u> 3.83 (1.44, 10.14) 27.18 (3.34, 221.18) 6.47 (3.61, 11.59) 5.87 (1.51, 22.77)	0.01	0.1 1 10 100 Normal lipase Increased lipase Odds Ratio M-H, Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CD	381 0.00; Chi ² = Z = 6.45 (P < Lipase >3 - Events 20 13 20 5	4.17, df= : 0.00001) * ULN 1 <u>Total</u> 26 14 65 9 114	592 8 (P = 0.84) Lipase <3 > <u>Events</u> 61 22 66 43	 ULN 131 68 1027 245 1471 	Weight 22.1% 4.8% 61.7% 11.4%	Odds Ratio <u>M-H, Random, 95% (1</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M-H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events	381 0.00; Chi ² = Z = 6.45 (P < Lipase >3 × Events 20 13 20 5 5	4.17, df= : 0.00001) * ULN 1 <u>Total</u> 26 14 65 9 114	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43 192	 ULN Total 68 1027 245 1471 	Weight 22.1% 4.8% 61.7% 11.4% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65]	0.01	0.1 1 10 10 Normal lipase Increased lipase	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² =	381 0.00; Chi ² = Z = 6.45 (P < Lipase >3 × Events 20 13 20 5 5 5 8 0.00; Chi ² =	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df=	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43 192 3 (P = 0.41	 ULN Total 131 68 1027 245 1471); l² = 0⁴ 	Weight 22.1% 4.8% 61.7% 11.4% 100.0%	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65]	0.01	Odds Ratio M-H, Random, 95% CI	
Total events Heterogeneity: Tau ^a = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect :	381 0.00; Chi [≈] = Z = 6.45 (P < <u>Events</u> 20 13 20 5 5 8 0.00; Chi [≈] = Z = 7.74 (P <	4.17, df= : 0.00001) * ULN 1 Total 26 14 65 9 114 2.89, df= : 0.00001)	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43 43 192 3 (P = 0.41)	 ULN Total 131 68 1027 245 1471); I² = 0⁴ 	Weight 22.1% 4.8% 61.7% 11.4% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65]	0.01	0.1 1 10 100 Normal lipase Increased lipase Odds Ratio M-H, Random, 95% CI	
Total events Heterogeneity: Tau ^a = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect :	381 0.00; Chi ^a = Z = 6.45 (P < <u>Events</u> 20 13 20 5 5 0.00; Chi ^a = Z = 7.74 (P <	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001)	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43 192 3 (P = 0.41)	 VLN Total 131 68 1027 245 1471); I² = 0⁴ 	Weight 22.1% 4.8% 61.7% 11.4% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65]	0.01	Odds Ratio M-H, Random, 95% CI 0.1 10 100 M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN	
Total events Heterogeneity: Tau ^a = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect :	381 0.00; Chi ^p = Z = 6.45 (P < Lipase >3) 20 13 20 5 5 8 0.00; Chi ^p = Z = 7.74 (P <	4.17, df= :0.00001) × ULN 1 <u>Total</u> 26 14 65 9 114 2.89, df= :0.00001) × ULN 2	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43 192 3 (P = 0.41)	(ULN <u>Total</u> 131 68 1027 245 1471); I ² = 09	Weight 22.1% 4.8% 61.7% 11.4% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65]	0.01	Odds Ratio 0.1 10 100 Normal lipase Increased lipase Odds Ratio M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Patio	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Anmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup	381 0.00; Chi [™] = Z = 6.45 (P < Lipase >3 + 20 13 20 5 5 58 0.00; Chi [™] = Z = 7.74 (P < Lipase >3 + Events	4.17, df= : 0.00001) * ULN 1 <u>Total</u> 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43 3 (P = 0.41) Lipase <3 > Events	 ULN Total 131 68 1027 245 1471); I² = 0⁴ ULN Total 	Weight 22.1% 4.8% 61.7% 11.4% 100.0%	Odds Ratio <u>M-H. Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio M-H. Random, 95% CI	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E <u>Study or Subgroup</u> Ahmed et al	381 0.00; Chi ^p = Z = 6.45 (P < Lipase >3 : 20 13 20 5 5 8 0.00; Chi ^p = Z = 7.74 (P < Lipase >3 : Events 17	4.17, df = : 0.00001) * ULN 1 Total 266 14 65 9 114 2.89, df = : 0.00001) * ULN 1 Total 26	592 8 (P = 0.84) Lipase <3 > 61 22 66 43 192 3 (P = 0.41) Lipase <3 > Events 24	 ULN Total 131 68 1027 245 1471); I² = 0° (ULN Total 131 	Weight 22.1% 4.8% 61.7% 11.4% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.271 [1.35, 7.90]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E <u>Study or Subgroup</u> Ahmed, et al Barlass, et al	381 0.00; Chi ^p = Z = 6.45 (P < Lipase >3 : 20 13 20 5 5 0.00; Chi ^p = Z = 7.74 (P < Lipase >3 : Events 17 11	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14	592 8 (P = 0.84) Lipase <3 > 61 22 66 43 192 3 (P = 0.41) Lipase <3 > Events 48 16	 ULN Total 131 68 1027 245 1471); I² = 0⁴ (ULN Total 68 	Weightt 22.1% 4.8% 61.7% 11.4% 100.0% %	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04]	0.01	Odds Ratio M-H, Random, 95% CI 0.1 10 100 M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M-H, Random, 95% CI	
Total events Heterogeneity: Tau ^a = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect : E <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Benias, et al	381 0.00; Chi ^p = Z = 6.45 (P < Lipase >3) 20 5 20 5 5 8 0.00; Chi ^p = Z = 7.74 (P < Lipase >3) Events 17 11 21	4.17, df= : 0.00001) * ULN 1 Total 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46	592 8 (P = 0.84) Lipase <3 , 22 66 43 192 3 (P = 0.41) Lipase <3 , Events 48 16 347	(ULN Total 131 68 1027 245 1471); I ² = 0 (ULN Total 131 68 1425	Weight 22.1% 4.8% 61.7% 11.4% 100.0% %	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio M-H, Random, 95% CI 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4,72]	0.01	0.1 1 10 100 Normal lipase Increased lipase Odds Ratio M-H, Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Benias, et al Benias, et al	381 0.00; Chi [™] = Z = 6.45 (P < Lipase >3 · 20 13 20 5 5 8 0.00; Chi [™] = Z = 7.74 (P < Lipase >3 · Events 17 11 21 69	4.17, df= : 0.00001; * ULN 1 26 14 65 9 114 2.89, df= : 0.00001; * ULN 1 Total 26 14 46 14 46 14 46 14 46 14 46 14 14 14 14 14 14 14 14 14 14	592 8 (P = 0.84) Events 61 22 61 22 63 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58	<pre>vULN <u>Total</u> 131 68 1027 245 1471 (vULN <u>Total</u> 131 131 1425 1425 1406</pre>	Weight 22.1% 4.8% 61.7% 11.4% 100.0% %	Odds Ratio <u>M-H. Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H. Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Benias, et al Singh, et al	381 0.00; Chi [™] = Z = 6.45 (P < Lipase >3 + 20 13 20 5 5 8 0.00; Chi [™] = Z = 7.74 (P < Lipase >3 + Events 17 11 21 69	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1406 1406	592 8 (P = 0.84) Lipase <3 > 61 22 66 43 3 (P = 0.41) Lipase <3 > Events 48 16 347 58	 ULN Total 131 68 1027 245 1471 (ULN Total 131 131 68 1425 1406 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% %	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Benias, et al Singh, et al Total (95% CI)	381 0.00; Chi [™] = Z = 6.45 (P < Lipase >3 : 20 13 20 5 5 8 0.00; Chi [™] = Z = 7.74 (P < Lipase >3 : Events 17 11 21 69	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1406 1492	592 8 (P = 0.84) Lipase <3 > 61 22 66 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58	<pre>vULN</pre>	Weightt 22.1% 4.8% 61.7% 11.4% 100.0% %	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03]	0.01	Odds Ratio M.H. Random, 95% CI 0.1 100 10 M.H. Random, 95% CI 0.1 100 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ^a = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect : E <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Benias, et al Singh, et al Total (95% CI) Total events	381 0.00; Chi ^p = Z = 6.45 (P < Lipase >3) 20 5 5 0.00; Chi ^p = Z = 7.74 (P < Lipase >3) Events 17 11 21 69 118	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1406 1492 46 00 000	592 8 (P = 0.84) Lipase <3 > Events 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58	 (ULN <u>Total</u> 131 68 1027 245 1471 1471 (ULN <u>Total</u> 1311 88 1425 1406 3030 (202) 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03]	0.01	Odds Ratio M-H, Random, 95% CI 0.1 10 100 M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M-H, Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Benias, et al Benias, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² =	381 0.00; Chi ^p = Z = 6.45 (P < Lipase >3) 20 13 20 5 5 8 0.00; Chi ^p = Z = 7.74 (P < Lipase >3) Events 17 11 21 69 118 0.47; Chi ^p = 7 - 2 6.4 (C	4.17, df= : 0.00001; * ULN 1 Total 26 14 65 9 114 2.89, df= : 0.00001; * ULN 1 Total 26 14 26 14 46 14 26 14 26 14 65 9 114 2.89, df= 26 14 65 9 114 2.89, df= 26 14 65 9 114 2.89, df= 2.6 14 65 9 114 2.89, df= 2.6 14 65 9 114 2.89, df= 2.6 14 65 9 14 14 65 9 14 14 14 14 14 14 14 14 14 14	592 8 (P = 0.84) Eupase <3 > 61 22 64 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58 469 = 3 (P = 0.0	 (ULN Total 131 (ULN 131 (ULN 245 1471 (); ² = 0' (ULN Total 131 (); ² = 0' (ULN 131 (); ² = 0' ();	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 23.7% 16.3% 23.4% 31.6% 100.0%	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio M-H, Random, 95% CI 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Barlass, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect :	$381 0.00; ChiP = Z = 6.45 (P < Lipase >3 \cdot2013205580.00; ChiP =Z = 7.74 (P <Lipase >3 \cdotEvents171121690.47; ChiP =Z = 2.54 (P =$	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1492 15.23, df: : 0.01)	592 8 (P = 0.84) Events 61 22 66 43 192 3 (P = 0.41) Events 48 16 347 58 469 = 3 (P = 0.0	 (ULN Total 131 68 1027 245 1471 (*ULN 131 68 1425 (*ULN 131 68 1425 1406 3030 (02); * = 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Anmed, et al Barlass, et al Caruso, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Singh, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect :	381 $0.00; Chip = Z = 6.45 (P < Lipase >3 + Events) 20 13 20 5 5 0.00; Chip = Z = 7.74 (P < Lipase >3 + Events) 17 11 21 69 118 0.47; Chip = Z = 2.54 (P = Z))$	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1406 1492 15.23, df : 0.01)	592 8 (P = 0.84) Events 61 22 66 43 3 (P = 0.41) Events 48 16 347 58 469 = 3 (P = 0.0	 (ULN Total 131 131 138 1027 245 1471 1471 (ULN Total 131 131 1425 1406 3030 102); I^a = 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03]	0.01	Odds Ratio M.H. Random, 95% CI 0.1 10 100 M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN	
Total events Heterogeneity: Tau ^a = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Total (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Singh, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect : F	381 0.00; Chi [™] = Z = 6.45 (P < Lipase >3 : 20 13 20 13 20 5 58 0.00; Chi [™] = Z = 7.74 (P < Lipase >3 : Events 17 11 21 69 118 0.47; Chi [™] = Z = 2.54 (P = Lipase >3 :	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1406 1492 15.23, df : 0.01) * ULN 1 * U	592 8 (P = 0.84) Lipase <3 > 61 22 66 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 >	 (ULN Total 131 68 1027 245 1471 (*ULN Total 131 68 1027 (*I=0) (*ULN 131 68 1425 (*ULN 3030 (*ULN 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0% 80%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio	0.01	Odds Ratio M.H. Random, 95% CI 0.1 100 10 M.H. Random, 95% CI 0.1 100 1 Lipase <3 × ULN Lipase >3 × ULN 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN 0.1 10 1 UDM Statio	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Barlass, et al Barlass, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F Study or Subgroup	381 0.00; Chi [₽] = Z = 6.45 (P < Lipase >3) 20 5 5 0.00; Chi [₽] = Z = 7.74 (P < Lipase >3) 17 11 21 69 118 0.47; Chi [₽] = Z = 2.54 (P = Lipase >3)	4.17, df =: 0.00001; • ULN 1 26 14 65 9 114 2.89, df =: 0.00001; • ULN 1 14 26 14 46 1406 1492 15.23, df : 0.01) • ULN 1 Total	592 8 (P = 0.84) Lipase <3 > 61 22 66 43 192 3 (P = 0.41) Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events	 (ULN <u>Total</u> 131 68 1027 245 1471 (IF=0) (ULN <u>Total</u> 131 68 1425 1406 (ULN <u>Total</u> (ULN <u>Total</u> 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 16.3% 28.4% 31.6% 100.0% 80% Weight	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio M-H, Random, 95% CI 1.32 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio M-H, Random, 95% CI	0.01	Odds Ratio M-H, Random, 95% CI 0.1 10 10 M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M-H, Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Benias, et al Be	381 0.00; Chi ^P = Z = 6.45 (P < Lipase >3 · 20 13 20 5 5 58 0.00; Chi ^P = Z = 7.74 (P < Lipase >3 · Events 17 11 21 69 118 0.47; Chi ^P = Z = 2.54 (P = Lipase >3 ·	4.17, df= : 0.00001; * ULN 1 26 14 65 9 114 2.89, df= : 0.00001; * ULN 1 1492 15.23, df : 0.01) * ULN 1 Total 152	592 8 (P = 0.84) Events 61 22 63 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events 215	 (ULN Total 131 68 1027 245 1471 (ULN 131 68 1471 (ULN 1406 3030 (02); F= (ULN Total 840 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weight 27.3%	Odds Ratio <u>M-H. Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H. Random, 95% CI</u> 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio <u>M-H. Random, 95% CI</u> 1.38 [0.95, 2.01]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	· 0] 0] • 1
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F Study or Subgroup Ahmed, et al Bansal, et al Bansal, et al	381 0.00; Chi [™] = Z = 6.45 (P < Lipase >3 · 20 13 20 5 58 0.00; Chi [™] = Z = 7.74 (P < Lipase >3 · Events 17 11 21 69 118 0.47; Chi [™] = Z = 2.54 (P = Lipase >3 · Events 49 2	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1492 15.23, df : 0.01) * ULN 1 Total 152 2 2 2	592 8 (P = 0.84) Events 61 22 66 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events 215	(ULN Total 131 68 1027 245 1471); * = 0' (ULN Total 131 68 1425 1406 3030 002); * =	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weight 27.3% 1.1%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio <u>M-H, Random, 95% CI</u> 1.38 [0.95, 2.01] 8.33 [0.36, 190.86]	0.01	Odds Ratio M.H. Random, 95% CI Odds Ratio 0.1 1 0 10 M.H. Random, 95% CI Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F Study or Subgroup Ahmed, et al Bansal, et al	$381 \\ 0.00; Chip = Z = 6.45 (P < Lipase >3) ; Events 20 13 20 5 58 0.00; Chip = Z = 7.74 (P < Lipase >3) ; Events 11 21 69 118 0.47; Chip = Z = 2.54 (P = Lipase >3) ; Events 49 2 9 2 9 2 9 2 9 2 9 2 2 2 2 2 2 2 2 2 2$	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 46 1406 1492 15.23, df : 0.01) * ULN 1 Total 26 14 46 14 46 1406 14 26 14 26 14 5 9 114 26 14 5 9 114 28 14 14 28 14 28 14 28 14 14 28 14 14 28 14 14 28 14 14 28 14 14 28 14 14 28 14 14 14 14 28 14 14 28 14 14 14 14 14 14 14 14 14 14	592 8 (P = 0.84) Lipase <3 > Events 61 22 66 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events 215 10 292 10 292	(ULN Total 131 68 1027 245 1471 131 68 1027 245 1471 131 68 1471 3030 02); ² = 0 ⁴ 4ULN Total 840 02); ² = 0 4ULN Total 840 27 1425 1406	Weightt 22.1% 4.8% 61.7% 11.4% 100.0% % Weightt 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weightt 27.3% 1.1% 13.8% 13.8%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio <u>M-H, Random, 95% CI</u> 1.38 [0.95, 2.01] 8.33 [0.36, 190.86] 0.94 [0.45, 1.98] 0.94 [0.45, 1.98] 0.95 [0.95] 0.95 [0.95] 0.9	0.01	Odds Ratio M.H. Random, 95% CI 0.1 10 10 M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Barlass, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F Study or Subgroup Ahmed, et al Bansal, et al Bansal, et al Bansal, et al Bansal, et al Bansal, et al Bansal, et al Caruso, et al Caruso, et al Caruso, et al	381 0.00; Chi ^p = Z = 6.45 (P < Lipase >3) 20 5 5 0.00; Chi ^p = Z = 7.74 (P < Lipase >3) 17 11 21 69 118 0.47; Chi ^p = Z = 2.54 (P = Lipase >3) Events 49 2 9	4.17, df= 0.00001; ULN 1 26 14 65 9 114 2.89, df= 0.00001; ULN 1 Total 26 14 46 1406 1492 15.23, df 0.01) ULN 1 Total 152 2 46 65 1405 152 2 46 1405 152 2 46 1405 152 2 46 1405 152 2 46 1405 152 2 46 1405 152 2 46 1405 152 1405 152 1405 152 1405 152 1405 152 1405 152 152 1405 152 1405 152 152 152 152 152 152 152 15	592 8 (P = 0.84) Lipase <3 > Events 1 22 66 43 192 3 (P = 0.41) Events 23 (P = 0.41) Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events 215 10 292 164	 (ULN <u>Total</u> 131 68 1027 245 1471 (ULN <u>Total</u> 131 68 1425 1406 (ULN <u>Total</u> 840 (ULN <u>Total</u> 1425 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weight 27.3% 1.1% 13.8% 19.8% 29.1%	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio M-H, Random, 95% CI 3.27 [1.35, 7.90] 11.32 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio M-H, Random, 95% CI 1.38 [0.95, 2.01] 8.33 [0.36, 190.86] 0.94 [0.45, 1.98] 2.51 [1.45, 4.34] 4.60 (4.52, 2.02]	0.01	Odds Ratio M.H. Random, 95% CI 0.1 10 10 M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Benias, et al Benias, et al Singh, et al Study or Subgroup Ahmed, et al Benias, et al Benias	381 0.00; Chi ^P = Z = 6.45 (P < Lipase >3 · 20 13 20 5 58 0.00; Chi ^P = Z = 7.74 (P < Lipase >3 · Events 17 11 69 118 0.47; Chi ^P = Z = 2.54 (P = Lipase >3 · Events 49 2 9 21 159 6	4.17, df= : 0.00001; * ULN 1 26 14 65 9 114 2.89, df= : 0.00001; * ULN 1 26 14 26 14 26 14 15 1492 15.23, df : 0.01) * ULN 1 152 2 46 65 1406 65 1406	592 8 (P = 0.84) Events 61 22 63 43 192 3 (P = 0.41) Lipase <3 > Events 48 16 347 58 48 16 347 58 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events 215 10 292 215 10 292 164	 (ULN Total 131 68 1027 245 1471 131 68 1425 (ULN Total 131 68 1425 (ULN 3030 (ILD) 68 1425 (ILD) 702); F= (ULN Total 840 27 1425 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 80% Weight 27.3% 1.1% 13.8% 33.1% 5.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio <u>M-H, Random, 95% CI</u> 1.38 [0.95, 2.01] 8.33 [0.36, 190.86] 0.94 [0.45, 1.98] 2.51 [1.45, 4.34] 1.60 [1.23, 2.07] 8.31 [1.52 50.07]	0.01	0.1 10 10 Normal lipase Increased lipase Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D Study or Subgroup Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Benias, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F Study or Subgroup Ahmed, et al Bansal, et al Bansal, et al Bansal, et al Singh, et al Total (et al Bansal, et al Singh, et al Totans, et al Caruso, et al Singh, et al	381 0.00; Chi [™] = Z = 6.45 (P < Lipase >3 · 20 13 20 5 58 0.00; Chi [™] = Z = 7.74 (P < Lipase >3 · Events 17 11 21 69 118 0.47; Chi [™] = Z = 2.54 (P = Lipase >3 · 2 - 2.54 (P = 2 - 2.54 (P = Lipase >3 · 2 - 2.54 (P = Lipase >3	4.17, df = : 0.00001; * ULN 1 26 14 65 9 114 2.89, df = : 0.00001; * ULN 1 Total 26 14 2.89, df = : 0.00001; * ULN 1 Total 1492 15.23, df : 0.01) * ULN 1 Total 152 2 46 65 1406 9	592 8 (P = 0.84) Events 61 22 64 43 192 3 (P = 0.41) Lipase <3 , Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 , Events 215 10 292 164 104 59	(ULN Total 131 68 1027 245 1471); * = 0' (ULN Total 131 68 1425 1406 3030 002); * = (ULN Total 840 27 1425 245	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weight 27.3% 1.1% 13.8% 19.8% 33.1% 5.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio <u>M-H, Random, 95% CI</u> 1.38 [0.95, 2.01] 8.33 [0.36, 190.86] 0.94 [0.45, 1.98] 2.51 [1.45, 4.34] 1.60 [1.23, 2.07] 6.31 [1.53, 25.99]	0.01	Odds Ratio M-H, Random, 95% CI Odds Ratio	
Total events Heterogeneity: Tau ² = Test for overall effect : D Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Ahmed, et al Barlass, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F Study or Subgroup Ahmed, et al Bansal, et al Bansal, et al Bansal, et al Singh, et al Troncone, et al Troncone, et al	$\begin{array}{c} 381\\ 0.00; Chi^{p} =\\ Z = 6.45 (P <\\ \hline Lipase >3 , \\ 20\\ 13\\ 20\\ 5\\ 5\\ 8\\ 0.00; Chi^{p} =\\ Z = 7.74 (P <\\ \hline Lipase >3 , \\ Chi^{p} =\\ Z = 7.74 (P <\\ \hline Lipase >3 , \\ 11\\ 21\\ 69\\ 118\\ 0.47; Chi^{p} =\\ Z = 2.54 (P =\\ \hline Lipase >3 , \\ \hline Events\\ 4\\ 9\\ 2\\ 9\\ 21\\ 159\\ 6\\ \end{array}$	4.17, df= : 0.00001) * ULN 1 26 14 65 9 114 2.89, df= : 0.00001) * ULN 1 Total 26 14 2.89, df= 14 46 1406 1492 15.23, df : 0.01) * ULN 1 Total 152 2 46 65 1406 9 1480	592 8 (P = 0.84) Events 61 22 66 43 3 (P = 0.41) Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events 215 10 292 164 104 59	<pre></pre> Total 131 68 1425 1406 3030 Total 840 27 1425 1027 	Weight 22.1% 4.8% 61.7% 11.4% 100.0% % Weight 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weight 27.3% 1.1% 13.8% 13.8% 13.8% 100.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio <u>M-H, Random, 95% CI</u> 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio <u>M-H, Random, 95% CI</u> 1.38 [0.95, 2.01] 8.33 [0.36, 190.86] 0.94 [0.45, 1.98] 2.51 [1.45, 4.34] 1.60 [1.23, 2.07] 6.31 [1.53, 25.99] 1.70 [1.22, 2.38]	0.01	Odds Ratio M.H. Random, 95% CI Odds Ratio 0.1 1 10 10 M.H. Random, 95% CI Odds Ratio M.H. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect : D Atmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E Study or Subgroup Atmed, et al Barlass, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F Study or Subgroup Atmed, et al Bansal, et al Troncone, et al Troncone, et al Troncone, et al Total (95% CI) Total events	381 $0.00; Chip = Z = 6.45 (P < Chi = 2 = Chi = 2 = 2 = 2 = 2 = 2 = 2 = 2 = 2 = 2 =$	4.17, df = 0.00001) * ULN 1 26 14 65 9 114 2.89, df = 0.00001) * ULN 1 Total 26 14 65 1406 46 1492 15.23, df 0.01) * ULN 1 Total 26 14 65 1406 9 165 1406 9 165 1406 9 165 1406 9 165 1406 9 165 1406 9 165 1406 9 165 1406 9 165 1406 14 14 14 14 14 14 14 14 14 14	592 8 (P = 0.84) Events 61 22 66 43 192 3 (P = 0.41) Events 48 16 347 58 469 = 3 (P = 0.0 Lipase <3 > Events 215 10 292 164 104 59 844	 (ULN Total 131 68 1027 245 1471 1471	Weightt 22.1% 4.8% 61.7% 11.4% 100.0% % Weightt 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weightt 27.3% 1.1% 13.8% 3.1.1% 5.0% 100.0%	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio M-H, Random, 95% CI 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio M-H, Random, 95% CI 1.38 [0.95, 2.01] 8.33 [0.36, 190.86] 0.94 [0.45, 1.98] 2.51 [1.45, 4.34] 1.60 [1.22, 2.73] 1.70 [1.22, 2.38]	0.01	Odds Ratio M.H. Random, 95% CI 0.1 10 10 M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI 0.1 10 1 Lipase <3 × ULN Lipase >3 × ULN	
Total events Heterogeneity: Tau ² = Test for overall effect : D <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Caruso, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : E <u>Study or Subgroup</u> Ahmed, et al Barlass, et al Benias, et al Singh, et al Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : F <u>Study or Subgroup</u> Ahmed, et al Bansal, et al Bansal, et al Bansal, et al Bansal, et al Singh, et al Troncone, et al Total (95% CI) Total events Heterogeneity: Tau ² = Total (95% CI) Total events Heterogeneity: Tau ² =	381 0.00; Chi [₽] = Z = 6.45 (P < Lipase >3) 20 5 5 0.00; Chi [₽] = Z = 7.74 (P < Lipase >3) Events 17 11 21 69 118 0.47; Chi [₽] = Z = 2.54 (P = Lipase >3) Events 49 2 9 6 0.07; Chi [₽] = Z = 2.54 (P = Lipase >3) 20 5 5 8 0.00; Chi [₽] = Z = 2.54 (P = Lipase >3) 6 6	4.17, df =: 0.00001; • ULN 1 26 14 65 9 114 2.89, df =: 0.00001; • ULN 1 14 26 14 26 14 46 1406 1492 15.23, df : 0.01) • ULN 1 Total 152 26 1406 9 165 1406 9 165 1406 9 165 1406 9 165 165 1406 9 165 1406 9 165 165 1406 9 165 165 165 165 165 165 165 165	592 8 (P = 0.84) Eupase <3 > 61 22 66 43 192 3 (P = 0.41) Eupase <3 > Events 48 16 347 58 469 = 3 (P = 0.0 Eupase <3 > Events 215 10 292 164 104 59 8844 5 (P = 0.08	 (ULN <u>Total</u> 131 68 1027 245 1471 131 68 1027 245 1471 131 68 1027 245 1471 131 68 1027 245 1471 131 68 1425 1406 3030 02); ² = 4 4 14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Weightt 22.1% 4.8% 61.7% 11.4% 100.0% % Weightt 23.7% 16.3% 28.4% 31.6% 100.0% 80% Weightt 27.3% 1.1% 13.8% 19.8% 33.1% 5.0%	Odds Ratio M-H, Random, 95% CI 3.83 [1.44, 10.14] 27.18 [3.34, 221.18] 6.47 [3.61, 11.59] 5.87 [1.51, 22.77] 6.10 [3.86, 9.65] Odds Ratio M-H, Random, 95% CI 3.27 [1.35, 7.90] 11.92 [2.96, 48.04] 2.61 [1.44, 4.72] 1.20 [0.84, 1.71] 2.76 [1.26, 6.03] Odds Ratio M-H, Random, 95% CI 1.38 [0.95, 2.01] 8.33 [0.36, 190.86] 0.94 [0.45, 1.98] 2.51 [1.45, 4.34] 1.60 [1.23, 2.59] 1.70 [1.22, 2.38]	0.01	Odds Ratio M.H. Random, 95% CI Odds Ratio M.H. Random, 95% CI Odds Ratio 0.1 1 10 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI Odds Ratio M.H. Random, 95% CI Odds Ratio M.H. Random, 95% CI Odds Ratio 0.1 1 0 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI Odds Ratio 0.1 1 0 1 Lipase <3 × ULN Lipase >3 × ULN Odds Ratio M.H. Random, 95% CI Odds Ratio 0.1 1 0 1 0.1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	

Fig. 4. Forest plot for clinical outcomes of patients with concomitant COVID-19 and hyperlipasemia. Increased (>ULN) vs normal levels: ICU admission (A), need for mechanical ventilation (B), and mortality (C). >3 × ULN vs < 3 × ULN levels: ICU admission (D), need for mechanical ventilation (E), and mortality (F).

19 infection causing hypotension and ischemic gut injury, mechanical ventilation, renal injury, and other consequences that can give rise to the elevation of pancreatic enzymes [4,12,19]. This is well illustrated by the higher prevalence in ICU patients compared to hospitalized non-ICU patients by subgroup analyses. In addition, comorbidities such as diabetes, which has been identified as an independent predictive factor for increased pancreatic enzymes [33], may also contribute to the difference. However, the significant between-study heterogeneity requires more prospective studies to validate our results.

This study also showed that patients with concomitant COVID-19 and increased pancreatic enzymes had a significantly worse outcome, including need for ICU admission, mechanical ventilation, and mortality. In addition, the pooled mortality of patients with increased pancreatic enzymes (either > ULN or >3 \times ULN) was higher than that of patients with acute pancreatitis reported in a previous meta-analysis [9]. The reason is unknown, but it suggests that elevation of serum pancreatic enzymes in some patients may be from critical illness. Altered gut lymph (from gut injury in acute illness) has been shown to cause enhanced systemic inflammatory response and multiple organ dysfunction [34]. For example, it is known that elevated levels of pancreatic lipase in the thoracic duct increase the risk of acute respiratory distress, possibly via toxic free fatty acids [35], which have been observed to increase in COVID-19 [36]. Fatty acids may worsen outcomes during COVID-19 by inducing cytokine storm and causing organ damage as in pancreatitis [37,38]. While the underlying mechanisms require further investigation, data from this study highlights the clinically important association between COVID-19 and increased pancreatic enzymes. The worse outcome of COVID-19 patients in whom pancreatic enzyme $>3 \times$ ULN supported the view of Inamdar et al. [39], who divided patients with concomitant COVID-19 and increased pancreatic enzymes into 3 groups: (1) patients with serum lipase and/or amylase of $<3 \times$ ULN, (2) patients with serum lipase and/or amylase of $>3 \times$ ULN, but do not meet the Atlanta criteria for acute pancreatitis, and (3) patients with acute pancreatitis meeting the Atlanta criteria.

The main limitation of the present study was lack of highquality studies. Most of them were retrospective in nature, and some had a small sample size with a low event rate, leading to heterogeneity between studies. In addition, the included studies had neither uniform study population nor uniform control groups, making the results possibly distorted. Since confounding factors may affect the prognosis of COVID-19, we may have not shown the real effect of increased pancreatic enzymes on COVID-19 in absence of multivariable analyses. But at least it reminds clinicians that these patients should be taken seriously. Despite these limitations, the rigorous inclusion criteria and size of the total cohort provide us a clear picture of patients with concomitant COVID-19 and increased pancreatic enzymes.

In conclusion, increased pancreatic enzymes should be studied as a risk factor for severity in COVID-19 infection. As such, serum lipase could prove to be helpful in monitoring COVID-19 and predicting outcomes as it has higher specificity.

Author contributions

Feng Yang: study concept, study design, data analysis, statistical analysis, drafting the manuscript, study supervision.

Yinlei Dong: data acquisition, data analysis.

Yecheng Xu: data acquisition, data analysis.

Yuting Huang: data acquisition, data analysis.

Yunting Fu: data acquisition, data analysis.

Tian Li: data acquisition, data analysis.

Chenyu Sun: data analysis, statistical analysis.

Sanjay Pandanaboyana: data analysis, critical revision of the manuscript.

John A Windsor: data analysis, critical revision of the manuscript.

Deliang Fu: study concept, critical revision of the manuscript; study supervision.

Fundings

Supported **by** the National Key R&D Program of China No.2017YFC1308604 (Dr Yang).

Declaration of competing interest

We declare no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.pan.2022.03.014.

References

- Hameed AM, Lam VW, Pleass HC. Significant elevations of serum lipase not caused by pancreatitis: a systematic review. HPB 2015;17(2):99–112.
- [2] Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia. Gastroenterology 2020;159(1):367-70.
- [3] McNabb-Baltar J, Jin DX, Grover AS, et al. Lipase elevation in patients with COVID-19. Am J Gastroenterol 2020;115(8):1286–8.
- [4] Troncone E, Salvatori S, Sena G, et al. Low frequency of acute pancreatitis in hospitalized COVID-19 patients. Pancreas 2021;50(3):393–8.
- [5] Müller JA, Groß R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab 2021;3(2): 149–65.
- [6] Samanta J, Gupta R, Singh MP, et al. Coronavirus disease 2019 and the pancreas. Pancreatology 2020;20(8):1567–75.
- [7] Schmid-Schönbein GW, Hugli TE. A new hypothesis for microvascular inflammation in shock and multiorgan failure: self-digestion by pancreatic enzymes. Microcirculation 2005;12(1):71–82.
- [8] Pandanaboyana S, Moir J, Leeds JS, et al. SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study. Gut 2021;70(6):1061–9.
- [9] Yang F, Huang Y, Li T, et al. Prevalence and outcomes of acute pancreatitis in COVID-19: a meta-analysis. gutjnl-2021-325941 Gut 2021 Oct 20. https:// doi.org/10.1136/gutjnl-2021-325941 [Epub ahead of print].
- [10] Ahmed A, Fisher JC, Pochapin MB, et al. Hyperlipasemia in absence of acute pancreatitis is associated with elevated D-dimer and adverse outcomes in COVID 19 disease. Pancreatology 2021;21(4):698–703.
- [11] Bansal P, Margekar SL, Suman V, et al. Pancreatic injury in COVID-19 patients. J Assoc Phys India 2020;68(12):58–60.
- [12] Barlass U, Wiliams B, Dhana K, et al. Marked elevation of lipase in COVID-19 disease: a cohort study. Clin Transl Gastroenterol 2020;11(7):e00215.
 [13] Bulthuis MC, Boxboorn L, Beudel M, et al. Acute paperatitis in COVID-19.
- [13] Bulthuis MC, Boxhoorn L, Beudel M, et al. Acute pancreatitis in COVID-19 patients: true risk? Scand J Gastroenterol 2021;56(5):585–7.
 [14] Aghemo A, Piovani D, Parigi TL, et al. COVID-19 digestive system involvement
- and clinical outcomes in a large academic hospital in Milan, Italy. Clin Gastroenterol Hepatol 2020;18(10):2366–8. e3.
- [15] Akkus C, Yilmaz H, Mizrak S, et al. Development of pancreatic injuries in the course of COVID-19. Acta Gastroenterol Belg 2020;83(4):585–92.
- [16] Bruno G, Fabrizio C, Santoro CR, et al. Pancreatic injury in the course of coronavirus disease 2019: a not-so-rare occurrence. J Med Virol 2021;93(1): 74–5.
- [17] Liu F, Long X, Zhang B, et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 2020;18(9):2128–2130.e2.
- [18] Pezzilli R, Centanni S, Mondoni M, et al. Patients with coronavirus disease 2019 interstitial pneumonia exhibit pancreatic hyperenzymemia and not acute pancreatitis. Pancreas 2021;50(5):732–5.
- [19] Ramsey ML, Krishna SG, Elmunzer BJ. Serum lipase elevations in COVID-19 patients reflect critical illness and not acute pancreatitis. Clin Gastroenterol Hepatol 2021;19(9):1982–7.
- [20] Rasch S, Herner A, Schmid RM, et al. High lipasemia is frequent in Covid-19 associated acute respiratory distress syndrome. Pancreatology 2021;21(1): 306-11.
- [21] Stephens JR, Wong JLC, Broomhead R, et al. Raised serum amylase in patients with COVID-19 may not be associated with pancreatitis. Br J Surg 2021;108(4):e152–3.
- [22] Benias PC, Inamdar S, Wee D, et al. Analysis of outcomes in COVID-19 patients

with varying degrees of hyperlipasemia. Pancreas 2021;50(9):1310-3.

- [23] Singh RR, Chhabra P, Kumta NA. Does hyperlipasemia predict worse clinical outcomes in COVID-19? A multicenter retrospective cohort study. J Clin Gastroenterol 2022;56(3):e227–31.
- [24] Ding P, Song B, Liu X, Fang X, Cai H, Zhang D, Zheng X. Elevated pancreatic enzymes in ICU patients with COVID-19 in Wuhan, China: a retrospective study. Front Med 2021;8:663646.
- [25] Bacaksız F, Ebik B, Ekin N, et al. Pancreatic damage in COVID-19: Why? How? Int J Clin Pract 2021;75(10):e14692.
- [26] Li G, Liu T, Jin G, et al. Serum amylase elevation is associated with adverse clinical outcomes in patients with coronavirus disease 2019. Aging (N Y) 2021;13(20):23442-58.
- [27] Caruso S, Aloisio E, Dolci A, et al. Lipase elevation in serum of COVID-19 patients: frequency, extent of increase and clinical value. Clin Chem Lab Med 2021;60(1):135-42.
- [28] Goyal H, Sachdeva S, Perisetti A, et al. Hyperlipasemia and potential pancreatic injury patterns in COVID-19: a marker of severity or innocent bystander? Gastroenterology 2021;160(3):946–8. e2.
- [29] Pandanaboyana S. Exploring Koch's postulate for SARS-CoV-2-induced acute pancreatitis: is it all about the ACE? Br J Surg 2021;108(8):879–81.
- [30] Bonney GK, Gao Y, Chew CA, et al. SARS-COV-2 associated acute pancreatitis: cause, consequence or epiphenomenon? Pancreatology 2020;20(5):1017–8.
- [31] Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study.

Lancet Microbe 2020;1(6):e245-53.

- [32] Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome : results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 2020;173(5):350-61.
- [33] Chaari A, Hakim KA, Rashed N, et al. Factors associated with increased pancreatic enzymes in septic patients: a prospective study. J Intensive Care 2017;5:44.
- [34] Windsor JA, Escott A, Brown L, et al. Novel strategies for the treatment of acute pancreatitis based on the determinants of severity. J Gastroenterol Hepatol 2017;32(11):1796–803.
- [35] Qin X, Dong W, Sharpe SM, et al. Role of lipase-generated free fatty acids in converting mesenteric lymph from a noncytotoxic to a cytotoxic fluid. Am J Physiol Gastrointest Liver Physiol 2012;303(8):G969–78.
- [36] Thomas T, Stefanoni D, Reisz JA, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight 2020;5(14):e140327.
- [37] El-Kurdi B, Khatua B, Rood C, et al. Mortality from coronavirus disease 2019 increases with unsaturated fat and may Be reduced by early calcium and albumin supplementation. Gastroenterology 2020;159(3):1015–8. e4.
- [38] Hegyi P, Szakács Z, Sahin-Tóth M. Lipotoxicity and cytokine storm in severe acute pancreatitis and COVID-19. Gastroenterology 2020;159(3):824–7.
- [39] Inamdar S, Trindade AJ, SARS-CoV-2-Induced pancreatitis is a rare but real entity. Clin Gastroenterol Hepatol 2021;19(10):2215–6.